Investors

Press Releases

ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids

September 15, 2021

-If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to address the clinical needs of…

Read more

ObsEva to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 7, 2021

GENEVA, Switzerland September 7, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies…

Read more

ObsEva Announces Second Quarter 2021 Financial Results and Business Update

August 5, 2021

-Linzagolix (Yselty®) for uterine fibroids: US New Drug Application filing planned in Q3:21; European marketing approval recommendation anticipated in Q4:21-…

Read more

ObsEva Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban for Improving Pregnancy and Live Birth Outcomes Following IVF

August 4, 2021

– A Combined Analysis of Pregnancy and Live Birth in more than 1800 IVF Patients Across Three Randomized, Placebo-Controlled Clinical…

Read more

ObsEva to Present at Upcoming Investor Conferences

August 3, 2021

GENEVA, Switzerland August 3, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies…

Read more

Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor

July 27, 2021

Every year, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation) [i]; agent is being…

Read more

ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting

July 2, 2021

-Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be presented in an ePoster and…

Read more

ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (linzagolix) for the Treatment of Severe Adenomyosis at ESHRE Virtual 37th Annual Meeting

June 30, 2021

-Two additional abstracts presented on data from ongoing clinical programs: Yselty for the treatment of uterine fibroids and nolasiban for…

Read more

ObsEva To Present Data on Two Clinical Development Programs at ESHRE Virtual 37th Annual Meeting

June 24, 2021

– Data from Phase 3 study of Yselty® (linzagolix) for the treatment of uterine fibroids to be discussed in an…

Read more

ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021

June 10, 2021

-PROLONG data demonstrating ebopiprant was well tolerated and showed early evidence of efficacy selected for presentation– – Phase 2b/3 adaptive…

Read more
 
 

Sign up for news

 
 

    * Type:


    InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












    Read our privacy policy here.


     

    Are you sure you want to leave ObsEva.com?

    We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

    Continue to link

    Disclaimer

    Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

    Continue

    Disclaimer

    Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

    Continue